Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis
نویسندگان
چکیده
منابع مشابه
Biologic monotherapy in the treatment of rheumatoid arthritis
Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) - preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is af...
متن کاملBiologic monotherapy for the treatment of rheumatoid arthritis
Methotrexate monotherapy for rheumatoid arthritis is considered efficacious and safe, but an inadequate treatment response and intolerance are common. Patients unresponsive to methotrexate or other disease-modifying antirheumatic drugs may receive biologic disease-modifying antirheumatic drugs (bDMARDs) as monotherapy, or in combination with methotrexate. Of the 17 bDMARD monotherapy clinical t...
متن کاملRheumatoid Arthritis: Early diagnosis and treatment outcomes
Rheumatoid arthritis (RA) is an inflammatory progressive disease which in the absence of appropriate treatment can lead to joint destruction and disability. Prognosis of RA may be predicted based on the presence of some clinical and laboratory evidences.New criteria for classification of RA provides opportunity for earlier treatment. Initiation of treatment particularly by combination of DMARDs...
متن کاملBiologic Treatment in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% of the adult population in all age groups, although the incidence peaks during the fifth decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, stiffness, loss of function and ...
متن کاملMonotherapy for rheumatoid arthritis treatment?
Sirs, I read with interest the paper (1) and the accompanying editorial (2) published in the Lancet regarding the ADACTA trial. However, there are issues with this editorial, which seems to reach conclusions not justified by the data from the trial. Monotherapy in RA may be a possibility for some patients (3) but which agent or agents should be preferred has not been studied in comparative stud...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2012
ISSN: 1462-0324,1462-0332
DOI: 10.1093/rheumatology/kes116